Posted by Michael Wonder on 28 Oct 2021
Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show
28 October 2021 - CytoDyn and its CEO Nader Pourhassan have known the company’s long delayed HIV drug was in far more trouble with the FDA than was disclosed to investors, according to new documents filed this week as part of an on-going civil lawsuit.
The documents reveal that in May 2020, CytoDyn submitted a marketing application for its drug called leronlimab with the FDA, despite knowing the filing was missing crucial information and was largely incomplete.
